Daxor Corp. (DXR) Receives NIH Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100 with the United States Department of Veterans Affairs

Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume Analysis guided management of acute decompensated heart failure (ADHF) utilizing the BVA-100 blood test.

Over 6 million Americans suffer from heart failure, one of the most prevalent and deadly diseases leading to nearly 1 million deaths and 1 million hospitalizations annually. The study’s primary objective is to determine the benefit of goal-directed care guided by Daxor’s blood volume measurement system, in addition to usual care, resulting in more appropriate treatment and consistent achievement of optimal blood volume.

“We are gratified to have received notification of intent to fund the study from the NIH so that work may commence immediately with the VA system for this landmark prospective study. Past published data has shown BVA-100 guided care has led to reductions in patient mortality of over 82% and 56% for readmissions. This grant and potential subsequent funding stages will result in the highest quality of clinical data driving adoption of Daxor’s unique technology broadly, as well as validation of Daxor’s patent-pending clinical guidance system”, said Michael Feldschuh, CEO and President of Daxor. “High rates of heart failure rehospitalization and mortality and high treatment costs have persisted for decades despite advances in care. The BVA-100 blood test provides a simple, inexpensive, and objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”

Dr. Jacob Joseph, Director of Heart Failure Program at VA Boston Healthcare System, Director of Clinical Research Partnerships and Innovations at the Massachusetts Veterans Epidemiology Research and Information Center-Division of Population Health & Genomic Medicine, and Associate Professor of Medicine at Harvard Medical School, will serve as the study’s Principal Investigator. “Optimal fluid stewardship is one of the most important and challenging goals of heart failure treatment,” Dr. Joseph added. “The purpose of this study is to determine if Blood Volume Analysis provides important information for improving care in this vulnerable population.”

“The timing of this study converges with our planned next-generation analyzer product development schedule, which includes production of both nuclear and novel fluorescing-based point-of-care testing options over the next year,” said Jonathan Feldschuh, Chief Scientific Officer of Daxor. “Our next-generation system promises to be even faster, easier, and expand use of our test into more clinical settings for more indications.”

For more information visit: ClinicalTrials.gov, Identifier: NCT04855097.

You May Also Be Interested In

• XOMA (XOMA) Earns $9M Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM
• HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
• Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio